IFx-Hu2.0
Phase 1Biologic
IFx-Hu2.0 is one of 117 biologic programs targeting Cutaneous Melanoma. It is currently in Phase 1.
3
Indications
6
Total Trials
2
Active Trials
116
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
91 competitors in Cutaneous Melanoma
#DrugCompanyPhaseTrials
1Tafinlar
NovartisPhase 3
Keytruda
Merck & Co.Phase 3
Yervoy
Bristol-Myers SquibbPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
DTIC-Dome
BayerPhase 3
Taxol
TevaPhase 3
PEG-Intron
Merck & Co.Phase 3
Intron a
Merck & Co.Phase 3
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Merkel Cell Carcinoma2 trials
Skin Cancer2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IFx-Hu2.0. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- TTuHURA Biosciences, Inc.